2.70
-0.10 (-3.41%)
| Previous Close | 2.79 |
| Open | 2.79 |
| Volume | 447,502 |
| Avg. Volume (3M) | 1,328,425 |
| Market Cap | 436,442,912 |
| Price / Book | 1.58 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -1.61 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 8.98 |
| Operating Cash Flow (TTM) | -199.43 M |
| Levered Free Cash Flow (TTM) | -108.00 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -79.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Neumora Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.90 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.57% |
| % Held by Institutions | 60.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mic Capital Management Uk Llp | 30 Jun 2025 | 4,460,700 |
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 30 Jun 2025 | 3,309,123 |
| Iconiq Capital, Llc | 30 Jun 2025 | 2,559,090 |
| Lunate Capital Ltd | 30 Jun 2025 | 2,124,143 |
| Lunate Holding Rsc Ltd | 31 Dec 2024 | 2,124,143 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Guggenheim, 419.48%) | Buy |
| Median | 11.00 (308.16%) | |
| Low | 8.00 (Needham, 196.85%) | Buy |
| Average | 11.00 (308.16%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 28 Oct 2025 | 8.00 (196.85%) | Buy | 2.59 |
| Guggenheim | 27 Oct 2025 | 14.00 (419.48%) | Buy | 2.69 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS X, LLC | 2.69 | - | 1,915,700 | 5,153,233 |
| ARCH VENTURE PARTNERS XII, LLC | 2.69 | - | 1,915,700 | 5,153,233 |
| BUROW KRISTINA | 2.69 | - | 1,915,700 | 5,153,233 |
| Aggregate Net Quantity | 5,747,100 | |||
| Aggregate Net Value ($) | 15,459,699 | |||
| Aggregate Avg. Buy ($) | 2.69 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ARCH VENTURE PARTNERS X, LLC | 27 Oct 2025 | Buy (+) | 1,915,700 | 2.69 | 5,153,233 | |
| ARCH VENTURE PARTNERS XII, LLC | 27 Oct 2025 | Buy (+) | 1,915,700 | 2.69 | 5,153,233 | |
| BUROW KRISTINA | Director | 27 Oct 2025 | Buy (+) | 1,915,700 | 2.69 | 5,153,233 |
| Date | Type | Details |
|---|---|---|
| 03 Nov 2025 | Announcement | Neumora Therapeutics to Participate in Upcoming Conferences in November |
| 27 Oct 2025 | Announcement | Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 |
| 27 Oct 2025 | Announcement | Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model |
| 01 Oct 2025 | Announcement | Neumora Therapeutics to Host Virtual R&D Day on October 27 |
| 02 Sep 2025 | Announcement | Neumora Therapeutics to Participate in Upcoming Conferences in September |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |